More Articles

Medicare data shows savings to be made with generics use Reports | Posted 22/05/2015

Despite generics accounting for far more claims in the US Medicare system than brand-name drugs, the total costs for each drug still came in much lower than costlier but much less used brand-name d...

Patients’ perceptions of HIV generics in France Generics/Research | Posted 22/05/2015

In a study of patient perceptions of HIV generics in France, Jacomet and co-authors found that while the majority of patients accepted antiretroviral generics, a third of the patients were openly o...

FDA issues another biosimilars Q&A guidance Guidelines | Posted 22/05/2015

On 13 May 2015, the US Food and Drug Administration (FDA) issued another question and answer guidance document for biosimilar applications in the US. The draft guidance contains a question on the i...

US generics manufacturers renew calls for labelling revisions Policies & Legislation | Posted 22/05/2015

The Generic Pharmaceutical Association (GPhA) has stepped up pressure on the US Food and Drug Administration (FDA) to update its proposed generics labelling requirements. According to GPhA, FDA sho...

Generics of high blood pressure medication launched Generics/News | Posted 22/05/2015

On 31 March 2015, generics majors Mylan, Sandoz and Teva Pharmaceutical Industries (Teva) announced the US launch of their respective generic amlodipine and valsartan combination tablets in four do...

Clinical trials for adalimumab biosimilars Biosimilars/Research | Posted 15/05/2015

As part of their investigation into biosimilars for the treatment of psoriasis, researchers from the Charité – Universitätsmedizin Berlin, Germany, carried out a systematic review into clinical tri...

Patients’ and physicians’ perceptions of HIV generics Generics/Research | Posted 15/05/2015

A study of adult HIV positive outpatients and their physicians in clinics across France found that a third of patients and a quarter of physicians are openly opposed to antiretroviral generics [1].

Iran approves its first rituximab biogeneric Biosimilars/News | Posted 15/05/2015

In May 2015, Iran’s National Regulatory Authority, the Food and Drug Organization (FDO), approved its first rituximab biogeneric (Zytux). The medicine received its marketing authorization based on...